JL in charge but I can say Cyrus was dead set against pursuing anything Covid related. Cyrus was right…resources limited, only take a bite out of the choicest apple…stay focused and not try to cure OHM’s master list all in one go. OHM’s logic is impeccable…phase 3 rather than phase 2, puts a lot of chips on the table but the bet is on a pivotal approvals phase 3, closer to approval. Challenge is FDA predilection to focus on HIV immune modulation, and perhaps the challenge of agreement on outcome measures with long COVID. Maybe we wade into HIV first, path of least resistance…maybe Amarex shows up with suitcases full of Benjamins too heavy to lift and we wade into both. Maybe partners show up, maybe there is a buyout…no crystal ball here. One thing I am clear on, I trust JL can thread the needle to success.